Company type
Limited Corporation (APS)
Established
1959
Size
Large
Employees
623
Revenue
2,346 MDKK
Gross profit
874 MDKK
Operating Profit (EBIT)
- DKK
Profit for the year
391 MDKK
Equity
1,391 MDKK
ad

More financial key figures and analyses?

In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!

Rank Profit for the year

Rank in industry
4/160
"Top 10%"
Rank in Denmark
353/314,003
"Top 10%"

Top management Top 3

Board Top 3

Mikkel Lyager Olsen 3Chairman of board
Bente Schmidt Nielsen 2Boardmember
Carl-Åke Carlsson 3Boardmember

Legal owners Top 3

100%Xellia Group Aps

Rights certificate

Selskabet tegnes af bestyrelsens formand i forening med et andet bestyrelsesmedlem, af et bestyrelsesmedlem i forening med en direktør, af fire bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.

Company information based on CVR

NameXellia Pharmaceuticals Aps
Alternate namesAxellia Pharmaceuticals Aps, A.L-Pharma Aps, A/S Dumex (Dumex Ltd.), A/S Dumex-Agro, A/S Dumex-Agro (A/S Dumex (Dumex Ltd.)) Reg.Nr. 35.458, A/S Dumovit, A/S Dumovit (A/S Dumex (Dumex Ltd.)) Reg.Nr. 35.574, A/S Vitapharm, A/S Vitapharm (A/S Dumex (Dumex Ltd.)) Reg.Nr. 35.575, Alpharma Aps, Aps Dumex, Aps Dumex (Dumex Ltd.), Aps Nopalco, Dumovit A/S, Dumovit Aps, Vitapharm A/S, Vitapharm Aps Show more
CVR61094628
AddressDalslandsgade 11, 2300 København S
IndustryManufacture of basic pharmaceutical products [211000]
Established31-03-1959 (62 yr)
Company typeLimited Corporation (APS)
Number of employees623 (Fin.Stmt)
Advertising protectionNo
AuditorPricewaterhousecoopers Statsautoriseret Revisionspartnerselskab since 01-07-2011
Financial statement period01-01 to 31-12
Company capital201,000,000 DKK
101,000,000 DKK (18-12-2003 - 16-07-2013)
100,000,000 DKK (26-06-2003 - 17-12-2003)
95,000,000 DKK (23-08-2000 - 25-06-2003)
100,000,000 DKK (21-07-1989 - 22-08-2000)
50,000,000 DKK (30-08-1987 - 20-07-1989)
Articles of assoc. last18-03-2014

Member of industries

Purpose

Selskabets formål er at drive fabrikation af og handel med medicinalvarer til human eller veterinær brug, finkemikalier, kosmetik, forskning og udvikling samt hermed beslægtet virksomhed enten direkte eller ved anbringelse af kapital i selskaber med ligende formål samt at virke som repræsentant eller alliancepartner for danske og udenlandske virksomheder inden for sådanne forretningsområder.

Financial Statement

 201920182017
Currency/unit000' DKK000' DKK000' DKK
Revenue
2,346,296
+24%
1,890,464
0%
1,897,063
+29%
Gross Profit
873,518
+51%
576,673
+9%
528,294
+1%
Profit for the year
390,722
-
-74,912
-
91,002
+169%
Equity
1,391,325
+38%
1,007,124
+18%
850,770
+12%
Total Assets
2,651,568
+9%
2,426,495
-4%
2,521,355
+5%

Mangement review

Business activities
Xellia Pharmaceuticals ApS (Xellia) is a specialty pharmaceutical company, focused on providing important anti-infective treatments against serious and often life-threatening infections. Xellia’s anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
Xellia is the world-leading provider of Vancomycin and Colistimethate Sodium and a leading provider of other important critical care anti-infectives, including Bacitracin, Daptomycin and Polymyxin B.

The majority of Finished Dosage Forms (FDF) in Xellia’s portfolio are injectable. However, Xellia also develops other formulations of its key products, aiming to improve customer value and meet patient needs.

Xellia has five state-of-the-art manufacturing facilities located in; Denmark, Hungary, China and in the U.S. Xellia’s FDF facilities are located in Denmark and the U.S.

Xellia has over 100 years’ experience in the development, manufacture and supply of generic fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and FDFs.

Xellia operates according to current Good Manufacturing Practice (cGMP) and Xellia’s facilities have received regulatory approval from all relevant authorities, including the U.S. Food and Drug Administration (FDA).

Xellia’s generic anti-infective business is built to meet the immediate and long-term requirements of the customers comprising branded, specialty and generic pharmaceutical companies in more than 70 countries around the world.

Xellia has several own- label products launched in the US institutional market and a strong performance in the global B2B market.

Further information about Xellia can be found at:
www.xellia.com
Recognition and measurement uncertainties
The recognition and measurement of items in the financial statements is not subject to any material uncertainty that could significantly impact the financial statement.
Business review
The company's income statement for the year ended 31 December 2019 shows a profit of TDKK 390,722, and the balance sheet at 31 December 2019 shows equity of TDKK 1,391,325.
Investments
In 2019, Xellia invested MDKK 22.6 in intangible assets. Furthermore Xellia capitalized investment in tangible assets of MDKK 101.5 to expansion and upgrade of the sterile manufacturing facilities that the company initiated in 2017. Xellia completed the construction of the new state-of-the-art multi-storey, building and have commenced the installation of the latest sterile manufacturing equipment and containment solutions.
Special risks apart from generally occurring risks in industry
Operating risks
The company experience competition in certain markets, which highlights the importance of continued delivery performance and price competitiveness.
Currency risks
As the company has significant activities in foreign countries, the company is affected by trends in exchange rates of a number of currencies. The company’s currency policy is to hedge expected net cash flow risk from currency exposures. The hedging is made primarily by forward exchange contracts for the next 12 - 24 months.
Development in activities and financial position
For the year ended 31 December 2019, the company achieved revenues of MDKK 2,346 and a net profit of
MDKK 390.7. The result was affected by investments in pipeline activities, impairment, and expansion of
production facilities and by financial charges.
Outlook
The company anticipates increase in revenue in 2020 compared to 2019 because of completion of strategic projects undertaken over the recent years. The exchange rate of the USD and other exchange rates might, however, influence the net profit/loss for 2020.
Profit/(loss) for the year relative to the expectations most recently expressed
The 2019 financial performance was in line with expectations. The Net Result for the year was MDKK 390.7
(2018: MDKK -74.9).
Significant events occurring after the end of the financial year
The company’s outlook for the future might be negatively affected by the COVID-19 outbreak and the measures taken by governments in most of the world to mitigate the impacts of the outbreak. However, as long as the company is able to supply anti-infective to its customers, the company will more likely than not see an increase in revenue and profit relative to expectations due to the increasing demand from health systems as hospital admittance rates increase.

Company Management has tried to estimate the effect of COVID-19 on the expected revenue and net profit of the company. It is, however, too early yet to give an opinion as to the extent of the negative implications.
24-03-2020

Map